Recent Advances and Perspectives in Cancer Drug Design
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Chemical Biology".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 1825
Special Issue Editors
Interests: bioinformatics; machine learning; metagenomics
Interests: computational genomics
Interests: bioinformatics; systems biology; biomedical data mining; protein structure and function; ncRNA interactions and functions; drug discovery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is one of the leading causes of death worldwide. The design of therapeutic drugs has become increasingly urgent and is a trend from the perspective of structural biology and molecular physics. Despite the advances in cancer biology and the continuous discovery of novel therapeutic targets, the development of effective new cancer drugs remains challenging due to the higher failure rate. Traditional drug discovery methods can be labor-intensive and time-consuming. Computational drug design, including structure-based and AI-based, has emerged as a powerful and promising technology for faster, cheaper, and more effective drug discovery.
In this Special Issue, the subtopics include, but are not limited to: novel understanding of cancer drugs; anticancer drug target prediction; approaches, tools and databases for drug discovery, design, and synthesis; machine learning methods for integrating multi-level omics data; statistical methods for integrating multi-level omics data; cancer drug sensitivity and resistance.
Dr. Liang Cheng
Dr. Mingxiang Teng
Dr. Lei Deng
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer drug
- drug target
- structure-based drug discovery
- artificial intelligence (AI) based drug discovery
- multi-level omics data
- drug sensitivity
- drug resistance
